FDA Approves First Hepatitis B Antisense Drug Hibsago
The GSK injectable offers a new mechanism to help select adults maintain viral control and potentially stop antiviral therapy.
Updated on Oct. 20, 2026 in Biotech
Live Poll
Do you trust that new medical treatments for chronic conditions represent genuine long-term health improvements?
The FDA has approved GSK’s Hibsago, the first antisense oligonucleotide treatment for chronic hepatitis B in adults without cirrhosis. The injectable therapy is designed for patients currently on antiviral medication who have hepatitis B surface antigen levels of 3,000 IU/mL or less.
Why it matters
As a novel antisense oligonucleotide, Hibsago offers a new mechanism to treat a chronic infection that can otherwise progress to cirrhosis or liver cancer. Its approval introduces a structured pathway for patients to potentially discontinue long-term antiviral reliance.
Clinical data showed 24% of patients met requirements to stop existing medication, while 19% maintained viral control 24 weeks after ending treatment. Eligibility is strictly capped at hepatitis B surface antigen levels of 3,000 IU/mL or less.
The players
GSK plc
A global biopharmaceutical company focusing on vaccines, specialty medicines, and general medicines with an extensive portfolio in infectious diseases.
FDA
The U.S. federal agency responsible for regulating food, tobacco, drugs, and medical devices to ensure public safety.
The details
Hibsago is an antisense oligonucleotide — a synthetic strand of genetic material that binds to specific RNA sequences to inhibit protein production. By targeting the viral genetic instructions, it prevents the hepatitis B virus from replicating and producing surface proteins. Patients administer the drug via subcutaneous injection over a 24-week course while maintaining their existing antiviral regimen.
Timeline
October 20, 2026: FDA grants formal approval for Hibsago.
The Tech Race
Hibsago’s approval follows its inclusion in the FDA Breakthrough Therapy designation program, which expedites the review of drugs showing substantial clinical improvement over existing options. It represents a shift toward genetic-based interventions in the competitive landscape of chronic liver disease management.
Patients must be adults without cirrhosis and have been on antiviral therapy for at least six months to be eligible. Clinicians will use the authorized Roche Elecsys HBsAg II quant II RxDx assay to verify patient eligibility based on surface antigen levels.
The takeaway
Hibsago provides a path for specific hepatitis B patients to pause chronic medication, contingent on achieving viral control. Stakeholders should monitor real-world performance data against the 19% viral control rate reported in initial clinical trials.
Further reading
For broader trends in genetic medicine, visit our Biotech section.
More information
Review the FDA official drug approval announcement for clinical safety details.
Live Poll
Do you trust that new medical treatments for chronic conditions represent genuine long-term health improvements?
